Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Spinal Cord Neoplasms 1Pinealoma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Choroid Plexus Carcinoma 1Central Nervous System Neoplasms 1

Interventions

Temozolomide 3Irinotecan 3tozuleristide 2selpercatinib 2lenvatinib 2gadobenic acid 2avelumab 2Radiation 2Paclitaxel 2Leflunomide 2Immunotherapy 2Gemcitabine 2Everolimus 2Cisplatin 2Carboplatin 2Cancer Vaccines 2Bevacizumab 2Adjuvants, Immunologic 2ridaforolimus 1regorafenib 1prinomastat 1pomalidomide 1perillyl alcohol 1pemigatinib 1pembrolizumab 1pamiparib 1omburtamab I-131 1irinotecan sucrosofate 1interferon gamma-1b 1infigratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Central Nervous System Neoplasms × perillyl alcohol × Clear all
NCT06357377 2026-01-14

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

Neonc Technologies, Inc.

Phase 1 Not yet recruiting
12 enrolled
CNS

Choroid Plexus Carcinoma, Glioma, Pinealoma, Spinal Cord Neoplasms, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡